Hypothesis

Mitochondrial DNA encodes conserved micropeptides that, when released into the cytosol, modulate nuclear histone acetylation and DNA methylation, thereby resetting epigenetic aging clocks. This retrograde signaling depends on the mitochondrial inner membrane protease OMA1 and is amplified under mild oxidative stress.

Mechanistic Basis

1. Recent work shows somatic mtDNA mutations drive aging phenotypes (1) and metabolic remodeling that accelerates tumorigenesis (2).
2. Mitochondrial stress activates OMA1, leading to cleavage of the peptide DELE1, which activates the integrated stress response (3). We propose a parallel pathway where OMA1 processes a conserved 12‑aa micropeptide (mtMP) that translocates to the nucleus.
3. In the nucleus, mtMP binds to the acetyltransferase p300/CBP, enhancing histone H3K27ac at promoters of longevity genes (e.g., SIRT6, FOXO3) and recruits TET2 to demethylate CpG islands, lowering epigenetic age (4).
4. Nuclear‑encoded mitophagy regulators (PINK1, Parkin) and metabolic genes (PGC‑1α) modulate the amplitude of this signal, explaining why mtDNA edits alone insufficiently affect resistance (5,6).
5. Low‑level heteroplasmy at OXPHOS subunits alters systemic glucose homeostasis (7), providing a physiological trigger for mtMP release.

Testable Predictions

• Overexpressing the mitochondrial‑targeted mtMP in mice will decrease hippocampal DNA methylation age by >10% after 6 months, irrespective of mtDNA heteroplasmy level.
• Pharmacological inhibition of OMA1 will block the anti‑aging effect of NAD+ boosters, confirming dependence on mitochondrial protease activity.
• CRISPR base editing of the mtMP coding sequence to a non‑functional version will abolish the lifespan extension seen with mtDNA‑targeted antioxidative therapies.
• In cancer cell lines, inducing mtMP expression will sensitize resistant tumors to docetaxel by restoring nuclear‑encoded mitophagy flux, measurable via LC3‑II turnover.

Experimental Design

• Generate a knock‑in mouse expressing a FLAG‑tagged mtMP under the constitutive mitochondrial promoter; include a control line with a scrambled peptide.
• Perform longitudinal epigenetic clock analysis (Horvath mouse clock) on blood, liver, and brain at 3, 6, 12 months.
• Treat cohorts with OMA1 inhibitor (e.g., AF‑I‑142) or vehicle; assess mtMP nuclear localization by immunofluorescence.
• Cross with Polg mutator mice to test rescue of premature aging phenotype.
• In vitro, use HEK293T cells with inducible mtMP; measure H3K27ac ChIP‑seq and RNA‑seq after docetaxel exposure; quantify viability.

Potential Outcomes & Falsifiability

If mtMP drives nuclear epigenetic reprogramming, we expect: (a) significant epigenetic age reduction in mtMP mice versus controls; (b) loss of effect with OMA1 inhibition or mtMP mutation; (c) enhanced chemosensitivity correlating with nuclear mtMP levels. Failure to observe any of these outcomes would falsify the hypothesis, indicating that mtDNA‑derived peptides do not directly influence nuclear aging pathways.

Broader Implication

This positions the mitochondrial genome not as a passive passenger but as an active epigenetic regulator, unifying mtDNA mutation burden with nuclear‑encoded quality control in aging and cancer resistance.